Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua Zaritsky

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Pediatric Radiology|April 10, 2016
Contrast-enhanced magnetic resonance venography in pediatric patients with chronic kidney disease: initial experience with ferumoxytolAarti Luhar, Sarah Khan, J Paul Finn, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 7, 2013
Short daily hemodialysis is associated with lower plasma FGF23 levels when compared with conventional hemodialysisJoshua Zaritsky, Anjay Rastogi, George Fischmann, et al.
Pediatric Nephrology (Berlin, Germany)|September 13, 2014
High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohortAnjali B Nayak, Aarti Luhar, Mark Hanudel, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 20, 2010
Reduction of serum hepcidin by hemodialysis in pediatric and adult patientsJoshua Zaritsky, Brian Young, Barbara Gales, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 2, 2009
Hepcidin--a potential novel biomarker for iron status in chronic kidney diseaseJoshua Zaritsky, Brian Young, He-Jing Wang, et al.
Frontiers in Pediatrics|December 19, 2019
Dextran-Sulfate Plasma Adsorption Lipoprotein Apheresis in Drug Resistant Primary Focal Segmental Glomerulosclerosis Patients: Results From a Prospective, Multicenter, Single-Arm Intervention StudyRupesh Raina, Vinod Krishnappa, Cheryl Sanchez-Kazi, et al.
Trials|February 4, 2026
Correction: Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studiesFranz Schaefer, Giovanni Montini, Hee Gyung Kang, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 9, 2011
Defining left ventricular hypertrophy in children on peritoneal dialysisDagmara Borzych, Sevcan A Bakkaloglu, Joshua Zaritsky, et al.
Pediatric Nephrology (Berlin, Germany)|March 2, 2021
Continued reduction in peritonitis rates in pediatric dialysis centers: results of the Standardizing Care to Improve Outcomes in Pediatric End Stage Renal Disease (SCOPE) CollaborativeAlicia M Neu, Troy Richardson, Heidi Gruhler De Souza, et al.
Trials|March 21, 2024
Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studiesFranz Schaefer, Giovanni Montini, Hee Gyung Kang, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Pediatric Radiology|April 10, 2016
Contrast-enhanced magnetic resonance venography in pediatric patients with chronic kidney disease: initial experience with ferumoxytolAarti Luhar, Sarah Khan, J Paul Finn, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 7, 2013
Short daily hemodialysis is associated with lower plasma FGF23 levels when compared with conventional hemodialysisJoshua Zaritsky, Anjay Rastogi, George Fischmann, et al.
Pediatric Nephrology (Berlin, Germany)|September 13, 2014
High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohortAnjali B Nayak, Aarti Luhar, Mark Hanudel, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 20, 2010
Reduction of serum hepcidin by hemodialysis in pediatric and adult patientsJoshua Zaritsky, Brian Young, Barbara Gales, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 2, 2009
Hepcidin--a potential novel biomarker for iron status in chronic kidney diseaseJoshua Zaritsky, Brian Young, He-Jing Wang, et al.
Frontiers in Pediatrics|December 19, 2019
Dextran-Sulfate Plasma Adsorption Lipoprotein Apheresis in Drug Resistant Primary Focal Segmental Glomerulosclerosis Patients: Results From a Prospective, Multicenter, Single-Arm Intervention StudyRupesh Raina, Vinod Krishnappa, Cheryl Sanchez-Kazi, et al.
Trials|February 4, 2026
Correction: Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studiesFranz Schaefer, Giovanni Montini, Hee Gyung Kang, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 9, 2011
Defining left ventricular hypertrophy in children on peritoneal dialysisDagmara Borzych, Sevcan A Bakkaloglu, Joshua Zaritsky, et al.
Pediatric Nephrology (Berlin, Germany)|March 2, 2021
Continued reduction in peritonitis rates in pediatric dialysis centers: results of the Standardizing Care to Improve Outcomes in Pediatric End Stage Renal Disease (SCOPE) CollaborativeAlicia M Neu, Troy Richardson, Heidi Gruhler De Souza, et al.
Trials|March 21, 2024
Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studiesFranz Schaefer, Giovanni Montini, Hee Gyung Kang, et al.
Pageof 3